There are currently 30 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
12/13/2024
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Register for Updates
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817
Recruiting
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +24 locations
Conditions: Alzheimer's Disease
Register for Updates
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT05040217
Recruiting
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
08/26/2024
Locations: University of California - San Diego, La Jolla, California +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
NCT05658913
Recruiting
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Alzheimer's Disease
Register for Updates
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
NCT02022943
Recruiting
The Alzheimer's Prevention Registry (www.endALZnow.org) will collect contact and demographic information on individuals. The objective is to provide information the latest news and advances in Alzheimer's prevention research, and to inform enrollees about research studies in their community. Enrolled individuals will receive regular email communications. As research studies become available, individuals will be notified via email with information as to how proceed should they be interested. Regi... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
08/05/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona
Conditions: Alzheimer's Disease, Dementia
Register for Updates
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
NCT04073628
Recruiting
To investigate the impact of a long-term light treatment intervention on sleep physiology and memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The goal is also to measure the impact of the lighting intervention on caregivers' sleep, cognition, depression, and quality of life.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/30/2024
Locations: Icahn School of Medicine at Mount Sinai, Albany, New York +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Alzheimer's Disease
Register for Updates
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
NCT04666077
Recruiting
This study compares different music therapy (MT) experiences and their impact on memory and language in patients with Alzheimer's disease and Mild Cognitive Impairment. The 12-month study will assess the role of common experiences involving familiar music and other pleasant events (blinded control) to benefit cognition and measure the quality of life for people with Alzheimer's disease and Mild Cognitive Impairment. Following screening, all participants will meet with a licensed music therapis... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/26/2024
Locations: Louis Armstrong Center for Music and Medicine, Mount Sinai Beth Israel, New York, New York +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573
Recruiting
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: University of Alabama in Birmingham, Birmingham, Alabama +5 locations
Conditions: Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Register for Updates
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
05/30/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Register for Updates
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
Recruiting
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
05/30/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +18 locations
Conditions: Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
Register for Updates
New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study
NCT04426539
Recruiting
New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Full list of Active Sites and Imaging Facilities, Philadelphia, Pennsylvania
Conditions: Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Register for Updates